November 12, 2025 a 06:00 pm
REGN: Fundamental Ratio Analysis - Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. has shown robust financial performance, benefiting from its diverse drug portfolio and extensive collaboration agreements. The company has a notable market presence and strong pipeline addressing a variety of medical needs. With consistent fundamentals and strong analyst ratings, REGN presents itself as an attractive investment opportunity in the biotechnology sector.
Fundamental Rating
The fundamental rating reflects Regeneron's solid financial foundation, with strengths in discounted cash flow and asset management.
| Category | Score | Visualization |
|---|---|---|
| Overall | 4 | |
| Discounted Cash Flow | 5 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 3 | |
| Price to Book | 3 |
Historical Rating
This section compares the recent fundamental scores with past data to highlight trends and improvements.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-12 | 4 | 5 | 4 | 5 | 2 | 3 | 3 |
| Previous | 0 | 5 | 4 | 5 | 2 | 3 | 3 |
Analyst Price Targets
Regeneron's stock has a strong analyst consensus with a focus on future growth potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| $865 | $584 | $723 | $712 |
Analyst Sentiment
The sentiment from analysts remains positive, with a majority recommending a buy.
| Recommendation | Count | Visualization |
|---|---|---|
| Buy | 34 | |
| Hold | 12 | |
| Sell | 1 |
Conclusion
Regeneron Pharmaceuticals, Inc. stands as a formidable entity in the biotechnology sector, driven by its extensive drug portfolio and strategic partnerships. The consistent high scores in discounted cash flow and return on assets indicate robust financial health. Despite some challenges related to debt-equity ratios, REGN's overall positive analyst sentiment and promising financials make it an attractive investment. The strong buy recommendations underscore its potential for growth amidst market volatility. Investors should still consider market risks and competitive pressures in the biotech landscape.